Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Dyadic International, Inc.: Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
Daijiworld

Australian scientists achieve breakthrough in gene-editing therapy that halves ‘Bad’ cholesterol

In a world-first human trial, Australian researchers have achieved a major milestone in heart disease prevention with a new ...

What 21 Analyst Ratings Have To Say About Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...
The Star

‘SME growth calls for simplified support’

PETALING JAYA: Revitalising small and medium-sized enterprises (SMEs) requires more than just slogans – it needs clear, simplified and actionable support mechanisms, says MCA vice-president Datuk ...